Pseudomonas testosteroni: new data about growth and steroid metabolismZEILLINGER, R; SPONA, J.FEMS microbiology letters. 1986, Vol 37, Num 2, pp 231-235, issn 0378-1097Article

PCR-mediated synthesis of exogenous competitors for quantitative RT-PCRSCHNEEBERGER, C; ZEILLINGER, R.BioTechniques. 1996, Vol 20, Num 3, pp 360-362, issn 0736-6205, 2 p.Article

BRCA1 gene mutations in sporadic ovarian carcinomas : Detection by PCR and reverse allele-specific oligonucleotide hybridizationDAN TONG; STIMPFL, M; REINTHALLER, A et al.Clinical chemistry (Baltimore, Md.). 1999, Vol 45, Num 7, pp 976-981, issn 0009-9147Article

Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCRSLIUTZ, G; EDER, H; KOELBL, H et al.Breast cancer research and treatment. 1996, Vol 40, Num 3, pp 257-263, issn 0167-6806Article

Agnus castus extracts inhibit prolactin secretion of rat pituitary cellsSLIUTZ, G; SPEISER, P; SCHULTZ, A. M et al.Hormone and metabolic research. 1993, Vol 25, Num 5, pp 253-255, issn 0018-5043Article

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-I signalling pathwayPILS, D; PINTER, A; KRAINER, M et al.British journal of cancer. 2007, Vol 96, Num 3, pp 485-491, issn 0007-0920, 7 p.Article

Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node-and steroid receptor positive breast cancer patientsKUCERA, E; SPEISER, P; REINER, A et al.European journal of cancer (1990). 1999, Vol 35, Num 3, pp 398-405, issn 0959-8049Article

A differential PCR system for the determination of CCND1 (Cyclin D1) gene amplification in head and neck squamous cell carcinomasSCHNEEBERGER, C; EDER, S; SWOBODA, H et al.Oral oncology (1997). 1998, Vol 34, Num 4, pp 257-260, issn 1368-8375Article

Cytosol concentrations of CD44 isoforms in breast cancer tissueHEFLER, L; TEMPFER, C; HAEUSLER, G et al.International journal of cancer. 1998, Vol 79, Num 5, pp 541-545, issn 0020-7136Article

Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinomaSCHMUTZLER, R. K; BIERHOFF, E; WERKHAUSEN, T et al.International journal of cancer. 1997, Vol 74, Num 3, pp 322-325, issn 0020-7136Article

A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignanciesSPEISER, P; GHAREHBAGHI-SCHNELL, E; ZEILLINGER, R et al.British journal of cancer. 1996, Vol 74, Num 2, pp 269-273, issn 0007-0920Article

Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell linesZEILLINGER, R; TANTSCHER, E; SCHNEEBERGER, C et al.Breast cancer research and treatment. 1996, Vol 40, Num 2, pp 205-207, issn 0167-6806Article

The serum tumor marker M3/M21 in the follow-up of breast cancer patientsTEMPFER, C; HANZAI, E; ZEILLINGER, R et al.Anticancer research. 1996, Vol 16, Num 5B, pp 3049-3052, issn 0250-7005Conference Paper

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients ― A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)RUSCITO, I; DIMITROVA, D; CACSIRE-TONG, D et al.European journal of cancer (1990). 2014, Vol 50, Num 12, pp 2090-2098, issn 0959-8049, 9 p.Article

Δ 133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancerHOFSTETTER, G; BERGER, A; SPEISER, P et al.British journal of cancer. 2011, Vol 105, Num 10, pp 1593-1599, issn 0007-0920, 7 p.Article

In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivityBAUTISTA, S; VALLES, H; WALKER, R. L et al.Clinical cancer research. 1998, Vol 4, Num 12, pp 2925-2929, issn 1078-0432Article

Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresisSLIUTZ, G; SCHMIDT, W; TEMPFER, C et al.Gynecologic oncology (Print). 1997, Vol 64, Num 1, pp 93-98, issn 0090-8258Article

EGFR and steroid receptors in ovarian carcinoma : Comparison with prognostic parameters and outcome of patientsFISCHER-COLBRIE, J; WITT, A; HEINZL, H et al.Anticancer research. 1997, Vol 17, Num 1B, pp 613-619, issn 0250-7005Article

Prostate specific antigen (PSA) in breast and ovarian cancerKUCERA, E; KAINZ, C; TEMPFER, C et al.Anticancer research. 1997, Vol 17, Num 6D, pp 4735-4737, issn 0250-7005Article

Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasiaTSCHUGGUEL, W; KNOGLER, W; CZERWENKA, K et al.British journal of cancer. 1996, Vol 74, Num 9, pp 1423-1426, issn 0007-0920Article

Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancerKIRCHWEGER, R; ZEILLINGER, R; SCHNEEBERGER, C et al.International journal of cancer. 1994, Vol 56, Num 2, pp 193-199, issn 0020-7136Article

HER-2 oncogene amplification and overall survival of breast carcinoma patientsKURY, F; SLIUTZ, G; HOLZNER, H et al.European journal of cancer (1990). 1990, Vol 26, Num 9, pp 946-949, issn 0959-8049Article

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activationBONDONG, S; KIEFEL, H; BRAICU, I et al.Annals of oncology. 2012, Vol 23, Num 7, pp 1795-1802, issn 0923-7534, 8 p.Article

Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancerDAN TONG; SCHNEEBERGER, C; CZERWENKA, K et al.Clinical cancer research. 1999, Vol 5, Num 6, pp 1497-1502, issn 1078-0432Article

Expression of mucins and cytokeratins in ovarian cancer cell linesSTIMPFL, M; SCHMID, B. C; SCHIEBEL, I et al.Cancer letters. 1999, Vol 145, Num 1-2, pp 133-141, issn 0304-3835Article